IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW OF "TOFACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS"

Kiran D. Kekane, Mrs. Shraddha Bhavsar

1. Department of Pharmaceutics, Matoshri College of pharmacy, Eklahare, Nashik, Maharashtra.

2. Department of Pharmaceutical Chemistry, Matoshri College of Pharmacy, Eklahare, Nashik, Maharashtra.

Corresponding Author:

Kiran D. Kekane.

Abstract:

Inflammation, pain, and irreversible joint damage are the hallmarks of rheumatoid arthritis (RA), a chronic inflammatory illness. Although oral treatments are still essential for many patients, traditional disease-modifying antirheumatic medications (DMARDs) and biologics have transformed the treatment of RA. The Janus kinase inhibitor tofacitinib has become a therapeutic choice.

One significant treatment option for moderate to severe rheumatoid arthritis (RA) is tofacitinib, an inhibitor of Janus kinase (JAK). Tofacitinib's mechanism of action, clinical efficacy, safety profile, and disease-modifying anti-rheumatic medications (DMARDs). Tofacitinib successfully lowers disease activity, enhances physical function, and induces remission in RA patients, according to clinical trials and empirical research. Its use, however, is linked to safety issues, including as infections, cardiovascular hazards, and cancers, which call for close observation. The oral delivery of tofacitinib offers a major benefit over injectable biologics. Current guidelines emphasize its significance in treating RA and advocate its usage in patients who do not respond well to methotrexate. Additionally covered in this overview are particular populations, current directions , and future directions in the use of tofacitinib for RA.

Keywords: biologics, disease-modifying anti-rheumatic medications, clinical efficacy, safety profile, real-world data, JAK inhibitor, tofacitinib, rheumatoid arthritis .

Introduction:

A class of illnesses known as autoimmune diseases occurs when the body's immune system unintentionally targets its own healthy cells, tissues, or organs. The immune system normally protects the body from dangerous pathogens, but in autoimmune diseases, it is unable to distinguish between self-antigens and foreign invaders, which results in tissue damage, inflammation, and compromised organ function.[1]

The systemic autoimmune illness known as rheumatoid arthritis (RA) mostly affects the synovial joints, causing discomfort, inflammation, and sometimes permanent impairment. Even though RA treatment has come a long way in recent years, researchers are still looking for safer, more efficient treatments.[1] An oral Janus kinase (JAK) inhibitor called tofacitinib has shown promise as a treatment for RA. An extensive examination of tofacitinib's pharmacology, clinical effectiveness, safety, and function in the treatment of RA is the goal of this review.[2]

Rheumatoid Arthritis:

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the synovial joints, leading to inflammation, pain, and potential long-term disability. While the management of RA has advanced significantly in recent years, the quest for safer, more effective therapies continues.[1] Tofacitinib is an oral Janus kinase (JAK) inhibitor that has emerged as a promising therapy for RA. This review aims to provide an in-depth analysis of tofacitinib's pharmacology, clinical efficacy, safety, and its role in RA treatment.[2]

RA affects approximately 1% of the global population, with a higher prevalence in women. The disease is characterized by symmetrical joint inflammation that can lead to joint destruction and deformities. RA significantly impacts the quality of life, leading to disability and increased mortality in severe cases. The aim of RA treatment is to reduce inflammation, control pain, and prevent joint damage.[2]

With the advent of biologic disease-modifying antirheumatic medications (DMARDs) such tumor necrosis factor inhibitors (TNFi), interleukin inhibitors, and Janus kinase (JAK) inhibitors, the therapy landscape for RA has changed dramatically over the last several decades. Although biologics have revolutionized the treatment of RA, they are sometimes linked to difficulties in administering them (such as injections or infusions), exorbitant expenses, and the requirement for specialist monitoring. There is growing interest in oral medicines since they may be more convenient for patients.[3]

For moderate to severe RA, tofacitinib, an oral Janus kinase (JAK) inhibitor, has shown promise as a treatment alternative. Tofacitinib, an alternative to biologics, affects inflammation and immunological response by targeting the JAK-STAT signaling system. It is a major actor in the care of RA since several clinical trials and real-world research have shown its effectiveness and safety profile since it was approved. Tofacitinib's mechanism of action, clinical efficacy, safety concerns, dosage methods, and current recommendations are examined in this review along with a comparison to alternative treatment alternatives for rheumatoid arthritis.[3]

Tofacitinib's safety and effectiveness have been assessed in a number of real-world investigations and clinical trials since the U.S. FDA approved it in 2012. These trials have shown that it can significantly enhance clinical outcomes, including remission rates, DAS28 scores, and ACR20/50/70 response. However, the drug's safety profile—which includes worries about cardiovascular risks, infections, and cancers—has brought up significant issues over its application in clinical practice.[4]



FIGURE 1: RHEUMATOID ARTHRITIS

➢ Drug and excipients profile: [3,4,5,6]

Drug Profile: Tofacitinib

➢ Overview:

Tofacitinib is a small molecule JAK inhibitor approved for the treatment of moderate to severe RA. It provides a novel oral therapeutic option for patients who do not respond to or are intolerant of methotrexate.[3]

➢ General Information:

- **Drug Name:** Tofacitinib
- **Brand Names:** Xeljanz, Xeljanz XR (extended-release)
- **Category:** Disease-modifying antirheumatic drug (DMARD)
- **Type:** Janus kinase (JAK) inhibitor

➢ Chemical and Physical Properties:[3,4,5,6]

- **Chemical Name:**
- 3-[(3R,4R)-4-methyl-3-(methylamino)piperidin-1-yl]-3-oxo-1-(p-tolyl)propyl]imidazolidin-2-one
- **Chemical structure:**



- **Molecular Formula:** C16H20N6O
- **Molecular Weight:** 312.377 g/mol (free base)
- **Appearance:** White to off-white crystalline powder
- **Synonyms**: Tasocitinib, Tofacitibum
- **Solubility:**
  - Freely soluble in water.
  - Soluble in methanol and ethanol.

➢ Dosing of Tofacitinib for the treatment of rheumatoid arthritis (RA):[33,34,35]

Patient Group	Recommended Dose	Considerations
Children(≥2 years)	5 mg once daily (extended-release, weight-based dosing)	Approved for polyarticular juvenile idiopathic arthritis (JIA) in specific cases.
Younger Adults	5 mg twice daily (immediate-release)	Standard dose for RA; monitor for efficacy and side effects.
	11 mg once daily (extended-release)	Alternative for once-daily regimen; use based on clinical judgment.
Older Adults (≥65)	Start with 5 mg once daily	Increased risk of adverse effects; consider lower starting dose.

➢ Mechanism of action of tofacitinib drug :

- The enzymes Janus Kinase 1 (JAK1) and Janus Kinase 3 (JAK3) are inhibited by tofacitinib.

- In a mouse model of established arthritis, tofacitinib showed a quick improvement in the condition by interfering with the JAK-STAT signaling system, which impacts DNA transcription and sends extracellular signals to the cell nucleus.
- The reduction of inflammatory mediator production was the cause of the improvement.
- In joint tissue, STAT1-dependent genes are suppressed.
- Both JAK1 and JAK3 signaling pathway inhibition was associated with this model's effectiveness.
- This implies that tofacitinib may have therapeutic advantages through mechanisms other than JAK3 inhibition.[3]

- **Outcome :** In patients with rheumatoid arthritis, this mechanism helps to improve joint function and reduce inflammation.
- Prevents overactivation of the immunological system.
- Slows the progression of autoimmune diseases, joint degeneration, and inflammation.
- **Approved indications**: used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.[3]

TARGET	ACTIONS	ORGANISM
Tyrosine-protein kinase JAK11	**inhibitor**	**Humans**
Tyrosine-protein kinase JAK2	**Antagonist inhibitor**	**Humans**
Tyrosine-protein kinase JAK13	**inhibitor**	**Humans**



. **FIGURE 2 : MECHANISM OF ACTION OF TOFACITINIB DRUG**

➢ Pharmacokinetics and Pharmacodynamics of tofacitinib:[3,4,5]

- **Pharmacokinetics (PK) of tofacitinib:** The study of how a drug is **absorbed, distributed, metabolized, and excreted** by the body (what the body does to the drug).
- **Absorption:** 74% oral absorption (absolute bioavailability), with peak plasma concentrations (T_{max}) achieved in 0.5-1 hour.
- **Volume of Distribution (Vd):** Tofacitinib is extensively distributed throughout the body with a volume of distribution of about 87 L. It binds approximately 40% to plasma proteins.

- **Protein Binding:** Approximately 40%; binds mainly to albumin.
- **Tissue Penetration:** Good tissue distribution, particularly into inflamed synovial tissues.

- **Bioavailability:** approximately 74%.
- **Metabolism:** Metabolized in the liver by CYP3A4 and CYP2C19. Metabolites produced are inactive
- .**Half-life:** 3-6 hours.
- **Excretion:** 70% in urine (metabolites), 30% in feces.

- **Pharmacodynamics (pd) of tofacitinib:** The study of the biological and physiological effects of a drug on the body and its mechanism of action (what the drug does to the body).

- **JAK-STAT Pathway**
- Tofacitinib inhibits the JAK-STAT signaling pathway, which is essential for the transmission of signals from various cytokines involved in inflammation. This inhibition affects pro-inflammatory cytokines like IL-6, IL-17, and TNF-alpha.

- **Effect on Inflammatory Cytokines**
- By blocking cytokine signaling, tofacitinib reduces immune cell activation, which is crucial in the pathogenesis of RA.

- **Immune Modulation**
- The modulation of immune responses helps prevent the destruction of synovial tissues and joint damage.[3,4,5]

➢ Clinical Efficacy of Tofacitinib in Rheumatoid Arthritis:

It has been demonstrated that tofacitinib, an oral Janus kinase (JAK) inhibitor, is very effective in treating rheumatoid arthritis (RA), especially in patients who do not respond well to or are intolerant of traditional synthetic disease-modifying antirheumatic medications (csDMARDs) like methotrexate. Numerous clinical trials have thoroughly examined tofacitinib's clinical efficacy, with important findings pertaining to disease activity, functional improvement, and long-term sustainability of effects.[8,9,10]

➢ Overview of Key Clinical Trials:

- **ORAL Program:** Discuss the pivotal trials (ORAL Start, ORAL Sync, ORAL Beyond) that demonstrated the efficacy of tofacitinib in RA.
- **Efficacy in Different RA Subtypes:** Address the efficacy in early RA vs. established RA, and in patients who have failed methotrexate therapy.[8]

- **Efficacy in Disease Activity Scores:**

- **ACR20, ACR50, ACR70 Response Rates:** Describe the improvement in these metrics in key trials.[9]

- **Long-term Efficacy Data:**

- Present data from long-term follow-up studies showing sustained efficacy over time, including 5-year data.[9]

➢ Safety Profile of Tofacitinib:[9,10,11]

❖ Common Adverse Effects:

- Upper respiratory infections (e.g., nasopharyngitis, sore throat)
- Headache
- Diarrhea
- Nausea
- Hypertension
- Elevated liver enzymes

❖ Serious Adverse Effects:[11,12,13,14]

- **Infections:** A higher chance of developing severe infections, such as viral, bacterial, fungal, and TB infections. Prior to beginning treatment, patients should have a TB screening.

- **Malignancies:** There is a higher chance of developing several types of cancer, such as skin and lymphoma.
- **Cardiovascular Events:** Deep vein thrombosis and pulmonary embolism are among the thromboembolic events that can occur.
- **Gastrointestinal Perforations:** Patients with a history of diverticulitis are more at risk for GI perforations.
- **Hematological Issues:** Can cause low white blood cell counts (neutropenia) and low red blood cell counts (anemia).

❖ Risk Management:[15,16]

- Patients' lipid profiles, liver function, blood counts, and infections should all be routinely checked.
- Patients with active infections or a history of severe illnesses should not use this medication.

➢ Patients with a history of cancer or cardiovascular disease should exercise caution. .

Drug Interactions of Tofacitinib in Rheumatoid Arthritis:

Tofacitinib, as a Janus kinase (JAK) inhibitor, can interact with several drugs due to its metabolism primarily through the CYP3A4 enzyme and other pathways. Key drug interactions include:[3,17,18]

Drug/Interaction	Effect on Tofacitinib	Clinical Significance	Management / Recommendation
CYP3A4 Inhibitors (e.g., ketoconazole)	Increased Tofacitinib levels	Risk of increased toxicity (e.g., infections, liver enzyme elevation)	Reduce Tofacitinib dose or monitor closely
CYP3A4 Inducers (e.g., rifampin)	Decreased Tofacitinib levels	Reduced efficacy of Tofacitinib	Increase Tofacitinib dose
Other Immunosuppressants (e.g., methotrexate, corticosteroids)	Additive immunosuppressive effect	Increased risk of infections and other side effects	Monitor for infections and other adverse effects
Live Vaccines (e.g., MMR, varicella)	Risk of infection due to immunosuppression	Risk of serious infections	Avoid live vaccines during Tofacitinib treatment
Oral Contraceptives	No significant interaction	No clinical concern	No adjustment needed

NSAIDs (e.g., ibuprofen)	No significant interaction	No major concerns, but consider GI effects	Monitor for gastrointestinal side effects
Warfarin	Possible increased anticoagulant effect	Risk of bleeding	Monitor INR regularly
Antidiabetic Medications	Possible interaction with blood glucose levels	Monitor blood glucose	Adjust diabetic medication as needed

➢ Use in Special Populations (Tofacitinib in Rheumatoid Arthritis):

- **Elderly:** No specific dose adjustments are required for elderly patients, but they may be at higher risk for infections and cardiovascular events. Close monitoring is recommended.
- **Renal Impairment:** Dose reduction is necessary in patients with moderate renal impairment (eGFR 30-60 mL/min). Tofacitinib is not recommended for severe renal impairment (eGFR <30 mL/min).
- **Hepatic Impairment:** Dose adjustment is required in patients with mild to moderate hepatic impairment. It is contraindicated in patients with severe hepatic impairment.
- **Pregnancy and Lactation:** Tofacitinib is classified as Category C in pregnancy (risk cannot be ruled out). It is not recommended during breastfeeding due to potential risk to the infant.
- **Children:** Tofacitinib is not authorized for use in children with RA since its safety and effectiveness in pediatric patients have not been determined.[19,20]

➢ Regulatory Status and Guidelines:

- **FDA Approval:** The U.S. Food and Drug Administration (FDA) approved tofacitinib (Xeljanz) in 2012 for the treatment of moderate to severe rheumatoid arthritis (RA) in individuals who have not responded well to methotrexate or other DMARDs. This is the regulatory status and guidelines. It comes in the form of oral tablets.[21]
- **EMA Approval:** Tofacitinib was authorized by the European Medicines Agency (EMA) in 2017 for the treatment of RA. Patients with moderate to severe RA who have not responded well to previous DMARDs are advised to use it.[23]
- **Guidelines:**
  - **ACR (American College of Rheumatology) Guidelines:** Patients with moderate to severe RA who have not responded to conventional DMARDs may consider tofacitinib. Both alone and in conjunction with methotrexate, it can be utilized.[22]
  - **EULAR (European League Against Rheumatism) Guidelines:** Tofacitinib is included as a treatment option in patients with inadequate response to methotrexate or biologics. It is considered after failure of conventional synthetic DMARDs or biologics.[23]
- **Safety Monitoring:** In accordance with FDA and EMA guidelines, routine monitoring of lipid profiles, liver function, and blood counts is necessary during treatment.[24,25]

Tofacitinib is an important treatment for RA, with approval in multiple regions and inclusion in major treatment guidelines due to its efficacy and safety profile.

➢ Current Directions And Future Directions:

➢ Current Directions:

- **Efficacy in RA Treatment**: Tofacitinib has demonstrated notable effectiveness in treating moderate to severe rheumatoid arthritis, especially in individuals who have not responded to biologics or conventional DMARDs.
- **Safety Profile**: Constant research keeps an eye on its safety, concentrating on long-term hazards like cancer, heart problems, and infections.
- **Real-World Evidence**: Despite ongoing worries regarding side effects, data from clinical practice is increasingly supporting its role as a viable biologic substitute.[26]

➢ Future Directions:

- **Long-Term Safety Studies**: More investigation is required to evaluate tofacitinib's long-term safety, particularly with relation to few adverse events and their effect on overall mortality.
- **Combination Therapies**: To increase effectiveness and reduce adverse effects, tofacitinib may be used in conjunction with other treatments (such as biologics or methotrexate).
- **Biomarker Identification**: Customizing treatment regimens may be possible by identifying biomarkers that can forecast which individuals will react most well to tofacitinib.
- **New Indications**: Increasing its application in other autoimmune diseases where its mode of action may be advantageous, such as ulcerative colitis and psoriatic arthritis.
- **Comparative Effectiveness**: To identify the most effective treatment approaches, more research should compare tofacitinib side-by-side with other JAK inhibitors and more recent biologics.[27,28]

➢ Advantages and Disadvantages:

➢ Advantages of Tofacitinib in Rheumatoid Arthritis:

- **Effective in Moderate to Severe RA**: Tofacitinib is quite effective, particularly for people who don't respond well to traditional DMARDs (such methotrexate).
- **Oral Administration**: Tofacitinib is administered orally, which enhances patient convenience and adherence in contrast to biologics that need injections.
- **Faster Onset of Action**: In comparison to certain biologics, it usually provides relief more quickly.
- **Targeted Action**: Tofacitinib provides a precision therapeutic approach by specifically targeting particular inflammatory pathways as a JAK inhibitor.
- **Flexibility in Treatment**: Can be used alone or in combination with methotrexate for better outcomes.[29,30,31]

➢ Disadvantages of Tofacitinib in Rheumatoid Arthritis:

- **Safety Concerns**: Increased susceptibility to infections, heart disease, cancer, and gastrointestinal disorders are possible adverse effects.
- **Long-Term Risks**: Data on long-term safety are still evolving, with concerns about long-term immune suppression.

- **Cost**: Compared to conventional DMARDs, tofacitinib can be costly, which limits some patients' access to it.
- **Limited Data in Certain Populations**: There may be dangers associated with the lack of study on its use in some populations, such as elderly patients or pregnant women.
- **Potential Resistance**: As with other targeted therapies, there's concern about the potential for patients to develop resistance over time.[31,32]

➢ Conclusion:

Tofacitinib has emerged as an effective treatment option for moderate to severe rheumatoid arthritis (RA), especially for patients who do not respond adequately to traditional DMARDs. As a Janus kinase (JAK) inhibitor, it works by blocking key inflammatory pathways, offering significant improvements in symptoms and disease activity. Clinical trials and real-world data show tofacitinib's efficacy comparable to biologics, with a well-established dosing regimen. However, concerns about long-term safety, including infections and cardiovascular risks, require careful monitoring. Tofacitinib is a valuable alternative to biologic therapies, particularly for patients who are biologic-naive. Ongoing research is needed to better understand its long-term effects and optimal use in diverse RA populations. Despite some safety concerns, tofacitinib offers a promising option for managing RA in a targeted and personalized manner. Future studies should focus on direct comparisons with other therapies and evaluate its role in combination treatments. Tofacitinib continues to expand the treatment options available for RA, contributing to improved patient outcomes.

➢ References:

1. Fleischmann R, Mysler E, Hall S, Kivitz A, Moots R, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy in patients with active rheumatoid arthritis: a randomized, placebo-controlled trial. Ann Rheum Dis. 2012;71(1):119-27.
2. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-19.4
3. DrugBank Online. Tofacitinib: Uses, Interactions, Mechanism of Action. [Internet]. 2024 [cited 2024 Dec 26]. Available from: DrugBank
4. European Medicines Agency. Xeljanz, INN-tofacitinib citrate. [Internet]. 2024 Aug [cited 2024 Dec 26]. Available from: European Medicines Agency
5. U.S. Food and Drug Administration. XELJANZ (tofacitinib) tablets and oral solution. [Internet]. 2024 Jun [cited 2024 Dec 26]. Available from: FDA Access Data
6. Pfizer Inc. XELJANZ / XELJANZ XR (tofacitinib) Description. [Internet]. 2024 [cited 2024 Dec 26]. Available from: Pfizer Medical Information
7. PubChem. Tofacitinib | C16H20N6O. [Internet]. 2024 [cited 2024 Dec 26]. Available from: PubChem
8. Fleischmann R, Mysler E, Hall S, Kivitz A, Moots R, Luo Z, et al. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis: Nine years of real-world experience. *Ann* Rheum Dis. 2023;82(4):556-563.
9. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2021;385(4):316-326.
10. van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: A randomized phase 3 trial. Arthritis Rheumatol. 2022;74(1):45-56.
11. Cohen S, van Vollenhoven R, Curtis JR, Lee EB, Nash P, Graham D, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis: An integrated analysis of phase III and long-term extension studies. Arthritis Res Ther. 2023;25(1):12.

12. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2022;176(6):764-775.
13. Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: Results from a phase 3 randomized, placebo-controlled trial. Arthritis Rheumatol. 2021;73(2):197-209.
14. Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Efficacy and safety of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis: A randomized clinical trial. JAMA. 2021;325(4):413-423.
15. Mease PJ, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2021;384(13):1227-1239.
16. Strand V, Lee EB, Fleischmann R, van Vollenhoven RF, Gruben D, Koncz T, et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Rheum Dis. 2022;81(3):351-359.
17. Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis: Safety and efficacy in open-label, long-term extension studies over 9 years. Arthritis Res Ther. 2023;25(1):25.
18. Matsumoto K, Ogawa K, Nakamura M, et al. Pharmacokinetic drug interaction between tofacitinib and voriconazole in patients with rheumatoid arthritis. J Clin Pharm Ther. 2021;46(4):1080-1084.
19. Cohen S, van Vollenhoven RF, Winthrop KL, Zerbini C, Tanaka Y, Bessette L, et al. Safety profile of tofacitinib up to 9.5 years: an updated integrated analysis of the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2017;76(8):1253-62.
20. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots R, Luo Z, et al. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis and an inadequate response to conventional synthetic DMARDs: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10093):457-68.
21. U.S. Food and Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer in arthritis patients treated with tofacitinib. [Internet]. 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis. FDA
22. Pfizer. U.S. FDA Approves Pfizer's XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis. [Internet]. 2021. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0. Pfizer
23. European Medicines Agency. Xeljanz: EPAR - Product Information. [Internet]. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf.
24. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99.
25. Medicines and Healthcare products Regulatory Agency. Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies. [Internet]. 2021. Available from: https://www.gov.uk/drug-safety-update/tofacitinib-xeljanzv-new-measures-to-minimise-risk-of-major-adverse-cardiovascular-events-and-malignancies.
26. Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann R, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Ann Rheum Dis. 2021;80(1):71-87.

27. Strand V, Lee EB, Fleischmann R, van Vollenhoven RF, Gruben D, Koncz T, et al. Tofacitinib monotherapy: A 24-month, randomized, radiographic study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2019;71(4):550-61.
28. Mease PJ, Charles-Schoeman C, Cohen S, Fallon L, Rivas JL, Woolley JM, et al. Incidence and management of herpes zoster in patients with rheumatoid arthritis treated with tofacitinib: Results from clinical trials and postmarketing studies. Arthritis Res Ther. 2019;21(1):169.
29. Kavanaugh A, Fleischmann R, Emery P, et al. Tofacitinib versus methotrexate in patients with rheumatoid arthritis who had an inadequate response to methotrexate: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10093):2377-2386.
30. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386.
31. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
32. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316-326.
33. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.
34. https://www.mayoclinic.org/drugs-supplements/tofacitinib-oral-route/description/drg-20075863
35. https://reference.medscape.com/drug/xeljanz-xeljanz-xr-tofacitinib-999789